CAI 株価分析 — Caris Life Sciences, Inc. Common Stock (Healthcare >> Biotechnology)
CAI に関するよくある質問
CAIのPER(株価収益率)は?
Caris Life Sciences, Inc. Common Stock(CAI)は現在PER 41.68倍で取引されています。
CAIのROE(自己資本利益率)は?
Caris Life Sciences, Inc. Common StockのROEは5.73%です。
CAIの配当利回りは?
Caris Life Sciences, Inc. Common Stockの配当利回りは0.00%です。
CAIの品質スコア(Quality Score)は?
当社のAIはCAIの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CAIは今が買い時ですか?
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CAIはどのセクターに属しますか?
Caris Life Sciences, Inc. Common StockはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
CAI AI Analysis Summary
Our AI summary for CAI: Caris Life Sciences, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 41.68, ROE of 5.73%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 16.32
Price
0.65
(4.15%)
Day Change
|
|
|---|
CAI, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.32 |
| PBV / Sector |
7.46 / 44,219.29
|
| Earning Per Share | 0.13 |
| PE / Sector |
41.68 / 19.28
|
| PEG or PE/Growth / Sector |
-1.53 / 1.23
|
| Average 1M Daily Value |
59.53 M
|
| Average 1W Daily Value |
70.04 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:17 |
| Symbol | CAI |
| Name | CARIS LIFE SCIENCES, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 282.68 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,429.61 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 750 West John Carpenter Freeway, Irving, TX, United States, 75039
Phone: 866 771 8946
Website: https://www.carislifesciences.com
Employees: 1,846
Sector: Healthcare >> Biotechnology
Description: Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google